With biosimilars of Eylea (aflibercept) expected to reach the Japanese market in November, all eyes are on whether the originator’s…
ORGANIZATION
JPMA to Investigate the Status of Application of Japanese PI Waiver
The Japan Pharmaceutical Manufacturers Association (JPMA) plans to run a follow-up survey to look into the status of companies’ operations following a key regulatory guidance in late 2023 to basically waive Japanese PI studies before going into multiregional clinical trials.…
To read the full story
Related Article
- PMDA Stresses Science-Based Decisions on Japanese PI Waivers: Symposium
August 5, 2025
- PMDA to Clarify Position on Japanese PI Trials at August Symposium amid Industry Confusion
July 10, 2025
- Japanese PI Waiver Good News to Mega Pharma and Emerging Players Alike: Pfizer Execs
January 21, 2025
- Japan Officially Drops Japanese PI Requirement before Global Trial Entry
December 26, 2023
- Japan to Basically Drop Japanese PI Requirement before Global Clinical Trials
September 14, 2023
- Approve 16 Pediatric Cancer Meds as Exceptional Step Beyond Law, Oncologist Urges
August 8, 2023
ORGANIZATION
- NPhA Urges Pharmacies to Provide Accurate Info on Acetaminophen Use during Pregnancy
October 6, 2025
- Japan Patient Group Calls for Dupixent Approval in Ichthyosis
October 6, 2025
- Think Tanks Urge Unique Value Framework for Regenerative Medicine in 2026 Reform
October 2, 2025
- JETRO Launches Japan Entry Program for Regenerative Medicine Startups
October 2, 2025
- Policy Veterans’ Group Calls for Inflation-Linked Drug Pricing in FY2026 Reform
October 1, 2025
In the dynamic pharmaceutical landscape, especially within the nuanced Japanese market, leadership hinges on acute awareness. This transcends surface-level observations, demanding a deep understanding of regulatory shifts, cultural sensitivities, and evolving patient needs. For leaders in this sector, particularly those…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…